These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 38853720

  • 1. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.
    Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, Moon MK, Kim DL, Kim TH, Ko E, Lee J, Kim SG.
    Diabetes Obes Metab; 2024 Sep; 26(9):3642-3652. PubMed ID: 38853720
    [Abstract] [Full Text] [Related]

  • 2. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 3. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, Chin A, Hansen L.
    Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
    [Abstract] [Full Text] [Related]

  • 4. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S, Catrinoiu D, Celiński A, Ekholm E, Cook W, Hirshberg B, Chen H, Iqbal N, Hansen L.
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Müller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sjöström CD, Jacob S, Seufert J, Dronamraju N, Csomós K.
    Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
    Mathieu C, Herrera Marmolejo M, González González JG, Hansen L, Chen H, Johnsson E, Garcia-Sanchez R, Iqbal N.
    Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
    Kim NH, Lim S, Kwak SH, Moon MK, Moon JS, Lee YH, Cho HC, Lee J, Kim SG.
    BMJ Open; 2018 Sep 24; 8(9):e022448. PubMed ID: 30249630
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob S.
    Diabetes Obes Metab; 2019 Sep 24; 21(9):2152-2162. PubMed ID: 31144431
    [Abstract] [Full Text] [Related]

  • 13. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL.
    Arch Endocrinol Metab; 2018 Aug 24; 62(4):424-430. PubMed ID: 30304106
    [Abstract] [Full Text] [Related]

  • 14. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N.
    Diabetes Care; 2015 Mar 24; 38(3):376-83. PubMed ID: 25352655
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, CV181-039 Investigators.
    Diabetes Obes Metab; 2009 Jun 24; 11(6):611-22. PubMed ID: 19515181
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N.
    Clin Drug Investig; 2013 Oct 24; 33(10):707-17. PubMed ID: 23949898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.